Table 1.
Description of the occurrence of hepatic steatosis among patients with chronic hepatitis C according to the characteristics evaluated and the results of the bivariate tests
| Parameter | Steatosis | OR | 95% CI | P | ||
|---|---|---|---|---|---|---|
| Absent (n = 125) | Present (n = 114) | Low | Upper | |||
| Age (years) | 1.038 | 1.014 | 1.061 | 0.001 | ||
| Mean ± SD | 53.1 ± 11.6 | 58.2 ± 11.8 | ||||
| Median (min-max) | 54 (30–76) | 61 (29–83) | ||||
| Gender, n (%) | 0.079 | |||||
| Female | 66 (47.5) | 73 (52.5) | 1.00 | |||
| Male | 59 (59) | 41 (41) | 0.63 | 0.37 | 1.06 | |
| HCV genotype, n (%) | 0.029 | |||||
| Non-3 | 110 (55.6) | 88 (44.4) | 1.00 | |||
| 3 | 15 (36.6) | 26 (63.4) | 2.17 | 1.08 | 4.34 | |
| Fibrosisa, n (%) | 0.002 | |||||
| 0–2 | 109 (57.7) | 80 (42.3) | 1.00 | |||
| 3–4 | 16 (32) | 34 (68) | 2.90 | 1.50 | 5.61 | |
| Siderosis, n (%) | 0.491 | |||||
| Absent | 100 (53.5) | 87 (46.5) | 1.00 | |||
| Present | 25 (48.1) | 27 (51.9) | 1.24 | 0.67 | 2.30 | |
| Inflammatory activitya, n (%) | <0.001 | |||||
| 0–1 | 62 (75.6) | 20 (24.4) | 1.00 | |||
| 2–3 | 63 (40.1) | 94 (59.9) | 4.63 | 2.55 | 8.40 | |
| ALT (U/L) | 1.008 | 1.002 | 1.014 | 0.012 | ||
| Mean ± SD | 54.1 ± 40.5 | 70 ± 51.4 | ||||
| Median (min-max) | 44 (11–296) | 54.5 (12–311) | ||||
| AST (U/L) | 1.013 | 1.005 | 1.022 | 0.003 | ||
| Mean ± SD | 42.1 ± 30.4 | 58.8 ± 45.5 | ||||
| Median (min-max) | 33 (14–225) | 46 (13–251) | ||||
| GGT (U/L) | 1.006 | 1.002 | 1.009 | 0.001 | ||
| Mean ± SD | 65.6 ± 61.1 | 113.8 ± 128.8 | ||||
| Median (min-max) | 46 (8–361) | 65.5 (10–733) | ||||
| Cholesterol (mg/dL) | 0.992 | 0.986 | 0.999 | 0.022 | ||
| Mean ± SD | 178.7 ± 43.8 | 166.2 ± 37.1 | ||||
| Median (min-max) | 174 (104–399) | 167.5 (69–252) | ||||
| LDL (mg/dL) | 0.989 | 0.981 | 0.997 | 0.005 | ||
| Mean ± SD | 101.8 ± 38.7 | 88.6 ± 31.1 | ||||
| Median (min-max) | 99 (29–276) | 86 (12–176) | ||||
| HDL (mg/dL) | 1.000 | 0.986 | 1.015 | 0.982 | ||
| Mean ± SD | 55.2 ± 17 | 55.2 ± 18.1 | ||||
| Median (min-max) | 54 (25–101) | 55 (21–110) | ||||
| VLDL (mg/dL) | 1.004 | 0.985 | 1.025 | 0.661 | ||
| Mean ± SD | 21.7 ± 11.7 | 22.4 ± 14 | ||||
| Median (min-max) | 19 (7–76) | 19 (5–105) | ||||
| Triglyceride (mg/dL) | 1.001 | 0.997 | 1.005 | 0.670 | ||
| Mean ± SD | 105.9 ± 52.2 | 109.3 ± 70 | ||||
| Median (min-max) | 97 (34–372) | 92.5 (35–502) | ||||
| BMI | 1.077 | 1.011 | 1.147 | 0.021 | ||
| Mean ± SD | 26 ± 3.9 | 27.3 ± 4.5 | ||||
| Median (min-max) | 25.7 (17.4–38.3) | 26.4 (18.5–40.2) | ||||
| HOMA-IR, n (%) | 0.011 | |||||
| < 3 | 88 (59.1) | 61 (40.9) | 1.00 | |||
| ≥ 3 | 34 (41.5) | 48 (58.5) | 2.04 | 1.18 | 3.52 | |
| MTTP, n (%) | 0.521 | |||||
| GG | 60 (54.5) | 50 (45.5) | 1.00 | |||
| GT/TT | 65 (50.4) | 64 (49.6) | 1.18 | 0.71 | 1.97 | |
Bivariate logistic regression, significance level of P < 0.10
aMetavir score